Atara biotherapeutics to present tab-cel® long-term clinical outcomes from a multicenter expanded access protocol (eap) study for patients with epstein-barr virus-associated post-transplant lymphoproliferative disease

Atara biotherapeutics, inc. announced that it will present long-term tab-cel® (tabelecleucel) clinical outcomes from a multicenter expanded access protocol (eap) study for patients with epstein-barr virus-associated post-transplant lymphoproliferative disease (ebv+ ptld). these results, along with findings described in three additional abstracts, will be presented at the 61stamerican society of hematology (ash) annual meeting & exposition, to be held december 7-10, 2019, in orlando, florida. twenty-six ebv+ ptld patients who failed prior rituximab treatment regimens were enrolled in a tab `cel® eap study (eap-201) as of june 2018, after which eap-201 was amended to focus on expanded access for patients with ebv+ ptld and other ebv+ diseases who are not eligible for atara’s ongoing tab `cel® phase 3 studies (eap-901, nct02822495 [1]). the findings presented here are as of june 3, 2019. consistent with prior studies, no tab-cel® related adverse events leading to discontinuation or death occurred.
ATRA Ratings Summary
ATRA Quant Ranking